LEIDEN, The Netherlands , Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the U.S. in the month of September: 2023 Wells Fargo Healthcare Conference, Boston , September 6-8 Sijmen de Vries, Chief Executive Officer, and Michael Levitan, VP Investor Relations and Corporate... Read More

Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency LEIDEN, The Netherlands , Aug. 9, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial in Japan evaluating leniolisib for the treatment of activated... Read More

LEIDEN, The Netherlands , July 18, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming's new Chairman. Pharming nominates Dr. Peters for the appointment as Non-Executive Director for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).... Read More

LEIDEN, The Netherlands , July 13, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30 , on Thursday, August 3, 2023 . Pharming will host a presentation for analysts and investors at 13:30 CEST / 07:30 EDT on August 3, 2023 . Dial in details for the... Read More

LEIDEN, The Netherlands , June 1, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. ("Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing. Pharming was... Read More

LEIDEN, The Netherlands , May 25, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following investor conferences in the month of June: Jefferies Healthcare Conference, New York , U.S., June 7 - 9 Pharming's CEO, Sijmen de Vries, will present on Thursday, June 8 at 10:30 EST / 16:30 CEST . A live webcast and replay of the... Read More

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues decreased by 9% to US$42.5 million , compared to the first quarter of 2022, primarily due to temporary reimbursement disruptions for some patients on government insurance programs. This issue, affecting all of the HAE market, has since resolved Continue to anticipate low... Read More

LEIDEN, Netherlands , April 11, 2023 /CNW/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States . Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare and progressive primary... Read More

LEIDEN, The Netherlands , March 30, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor , will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York . Pharming's CEO and CCO will take part in a fireside chat on April... Read More

APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older Joenja® is expected to launch in the US in early April Pharming will host a conference call for investors and analysts on March 27 at 14:00 CEST / 08:00 EST LEIDEN, The Netherlands , March 24, 2023 /CNW/ --... Read More

The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands , Feb. 21, 2023 /CNW/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an... Read More

EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands , Feb. 16, 2023 /CNW/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) has decided to shift its assessment of the Marketing Authorisation Application (MAA) for leniolisib... Read More

V. Koneti Rao , MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial LEIDEN, Netherlands , Dec. 15, 2022 /CNW/ -- Pharming Group N.V. ("Pharming" or "the... Read More

Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency LEIDEN, Netherlands , Dec. 7, 2022 /CNW/ -- Pharming Group N.V. ( "Pharming" or "the Company") (EURONEXT... Read More